Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 0.63 |
| ▸ | EZH1 | Q92800 | 4/20 | 0.54 |
| ▸ | EED | O75530 | 5/20 | 0.53 |
| ▸ | SUZ12 | Q15022 | 5/20 | 0.53 |
| ▸ | RBBP4 | Q09028 | 4/20 | 0.53 |
| ▸ | AEBP2 | Q6ZN18 | 4/20 | 0.53 |
| ▸ | RBBP7 | Q16576 | 2/20 | 0.53 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.49 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16899507 | 0.92 | EZH2 (0.62) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL16899549 | 0.91 | EZH2 (0.58) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL16899615 | 0.90 | EZH2 (0.62) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL16899451 | 0.89 | EZH2 (0.72) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL16899556 | 0.88 | EZH2 (0.60) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL16899505 | 0.85 | EZH2 (0.86) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL16899624 | 0.82 | EZH2 (0.58) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL16899620 | 0.80 | EZH2 (0.87) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL16899579 | 0.78 | EZH2 (0.84) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL16899515 | 0.78 | EZH2 (0.86) | EZH2EZH1EEDSUZ12RBBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015104677-A1 | HETEROCYCLIC COMPOUNDS AS EZH2 INHIBITORS | Piramal Enterprises Limited (IN) | 2015-07-16 | — | — | WO | disclosed |